Shahrokh F. Shariat, MD
Associate Professor, Weill Cornell Medical Center, New York-Presbyterian Hospital
The focus of Dr. Shariats research during the past decade has been the development of molecular biomarkers that help with the early discovery and characterization of the biological and clinical aggressiveness of bladder cancer. He has contributed more than 330 peer-reviewed publications, predominantly in the area of bladder and prostate cancer, to the scientific literature. He holds multiple United States and international patents for molecular biomarkers. Most recently, he has been the principal investigator of several collaborative networks such as the Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelail Carcinoma Collaboration. His research relies on close collaboration with scientists and physician scientists in urology, medical oncology, and molecular biology. His laboratory has used a variety of techniques including RT-PCR, laser capture microdissection, high density tissue microarrays, SMP arrays, tiling arrays, and cNDA expression arrays in combination with clinical and morphologic parameters to identify significant associations.
Minimal invasive instrumental therapy for benign prostatic hyperplasia. Minimal invasive instrumental focal treatment modalities for prostate cancer. Gene and vaccine therapies for urologic diseases with focus on bladder and prostate cancers. Detection and testing of prognostic/predictive value of clinically occult micrometastases in advanced prostate cancer. Research in prostate and bladder cancer- molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research. Integrative epigenomics in bladder cancer. Understanding, predicting. and overcoming resistance to cisplatin in bladder cancer. Intravesical application of nanoparticle-mediated microwave thermotherapy (nTUMT) for treatment of bladder cancer.